New Inhibitor Shows Promise Against Metastatic Prostate Cancer
Stony Brook-led team receives $4.2 million NCI grant to advance research
When prostate cancer spreads it is often a deadly disease, but now a Stony Brook University-led research team believes a new approach that inhibits a specific fatty acid binding protein (FABP) may be the key to halting disease progression. Their research results on FABP5 inhibitors as promising therapeutic agents against metastatic prostate cancer led to a new five-year grant from the National Cancer Institute (NCI) totaling $4.2 million to advance the research to 2025.
Lead investigator Iwao Ojima, PhD, Distinguished Professor of Chemistry and Director of the Institute of Chemical Biology and Drug Discovery (ICB&DD), along with colleagues at Stony Brook and Cold Spring Harbor Laboratory, in collaboration with Artelo Biosciences, are investigating FABPs in the treatment of inflammation, pain and against certain cancers, as drug targets themselves or in combination with current chemotherapy treatments.
Read the full article. (Published: 1/29/20)
Creating 3D Digital Pathology to Advance Cancer Research, Diagnostic Practices
Fusheng Wang, PhD, Associate Professor in the Departments of Biomedical Informatics and Computer Science at Stony Brook University and colleagues nationally have received a $1.14 million grant from the National Cancer Institute (NCI) to research 3D computational pathology. The purpose of the research is to work toward revolutionizing digital pathology from 2D to 3D imagery, which would improve the efficiency and accuracy of clinical diagnosis, particularly in the context of cancer.
Read the full article. (Published: 9/23/19)
MicroRNA-based Therapy May Be New Weapon to Combat Cancer
A technology that manipulates microRNAs (miRNAs) developed by Jingfang Ju, PhD, a biochemist and Professor in the Department of Pathology at the Renaissance School of Medicine at Stony Brook University, and colleagues has shown promise when used as anti-cancer therapeutic. The method may prove to be particularly effective against chemotherapy resistant cancers such as colorectal cancer. To advance the science of this method and develop miRNA-based drugs, the technology has been licensed to Curamir Therapeutics Inc., a biotechnology company, through an agreement with the Research Foundation of the State University of New York.
Read the fill article. (Published: 9/18/19)
Drug Designed to Treat Metastatic Pancreatic Cancer May Help Extend Life
Clinical Trial Provided at Stony Brook Cancer Center
A drug developed by researchers at the Renaissance School of Medicine at Stony Brook University that targets enzymes involved in the development of pancreatic cancer cells is showing promise for improved treatment of metastatic pancreatic cancer. The drug, called CPI-613 (known as Devimistat), is being combined with the standard chemotherapy regimen (FOLFIRINOX) to treat pancreatic cancer. The Stony Brook Cancer Center has opened a clinical trial with this drug combination to treat patients with metastatic disease.
Read the full article. (Published: 9/3/19)
Research Points Toward New Treatments for Dangerous Triple-Negative Breast Cancer
A Stony Brook-led team of researchers has identified a gene that could offer new hope for treating triple-negative breast cancer, the most aggressive subtype of the disease.
Led by Lori Chan, PhD, Assistant Professor in the Department of Pharmacological Sciences in the Renaissance School of Medicine at Stony Brook University, the researchers have identified a specific gene involved in the cancer stem cell (CSC) population process of triple-negative breast cancer. By blocking this gene’s action, tumor response to chemotherapy is improved. Their findings, published in Cell Death & Disease, illustrate a potential new way to treat incurable triple-negative breast cancer.
Read the full article. (Published: 3/28/19)
Study Probes Effect of Anesthesia on Breast Cancer Outcomes
A Stony Brook-led study will investigate where anesthesia management during breast cancer surgery affects long-term patient outcomes
Surgery offers the best hope to cure breast cancer when disease does not spread. However, breast cancer that spreads to distant organs accounts for most of breast cancer deaths. Therefore, researchers continue to investigate how breast cancer metastasizes and what causes or affects disease spread.
Jun Lin, MD, PhD, a Professor in the Department of Anesthesiology at the Renaissance School of Medicine at Stony Brook University, leads a research team studying the effects of anesthetics on metastasis following breast cancer surgery.
Read the full article. (Published: 2/19/19)
Lung Cancer Survivor Rates Higher Using Multidisciplinary Care Model
Published study of more than 4,000 patients reveals better survival compared to standard care
An investigation of short-term and long-term survival outcomes of more than 4,000 lung cancer patients reveals that patients treated under a multidisciplinary model of care have significantly higher survival rates at one, three, five, and 10 years post diagnosis compared to patients treated with a standard or traditional model of care. The study, published online in Clinical Lung Cancer, was conducted by investigators at the Lung Cancer Evaluation Center (LCEC) at Stony Brook University Cancer Center.
Read full article
Removing the Most Common p53 Mutation in Colorectal Cancer Halts Disease Progression
By genetically manipulating and removing the most common mutant form of the p53 gene that promotes colorectal cancer in humans, an international team of scientists demonstrated that this therapy reduces tumor growth and tissue invasion. Led by Ute Moll, MD, Professor and cancer biologist in the Department of Pathology at Stony Brook University School of Medicine, the findings are published in Cancer Cell.
Read full article
Understanding Breast Cancer – Using Advanced Imaging to Unravel its Molecular Secrets
With breast cancer, the most common form of cancer in women globally, scientists at Stony Brook University, are on a mission to establish how the disease starts and progresses at the detailed molecular level.
Read full article
Targeting K17 in Pancreatic Cancer
Drs. Kenneth Shroyer and Luisa Escobar-Hoyos receive $500,000 from PanCAN to advance research
Keratin 17 (K17), a protein that promotes cancer, may prove to be a key target gene in the battle against pancreatic cancer. New research involving K17 as a therapeutic target against this lethal disease is being conducted by Kenneth Shroyer, MD, PhD, the Marvin Kuschner Professor and Chair of Pathology at Stony Brook Medicine, and Luisa Escobar-Hoyos, PhD, Assistant Professor and Co-Director of the Pathology Translational Research Lab. The Pancreatic Cancer Action Network (PanCAN) awarded Drs. Shroyer and Escobar-Hoyas a $500,000 grant to carry out this research. This is the first time a PanCAN grant has been awarded to Stony Brook University. The two-year award will begin July 1, 2018.
Read full article
New Non-Invasive Test For Urothelial Cancer Emerging
Urothelial cancers of the bladder and upper urinary tract are among the most common cancers encountered worldwide. In the United States, urothelial cancers are among the most costly cancers to treat. With early diagnosis, followed by surgery, most urothelial cancers can be cured. Now an international team of cancer researchers including Kate Dickman, PhD, of the Department of Pharmacological Sciences and Medicine/Nephrology at Stony Brook University School of Medicine have developed a highly sensitive and specific non-invasive test as a biomarker for early detection of urothelial cancers. Details of this method known as UroSEEK, are published in eLife.
Read full article
Images of Polyps Plus Tissue Data May Help Predict Cancer
By using computed tomography colonography (CTC), also known as virtual colonoscopy, to image many types of polyps, and matching those images to detailed gene expression data of those polyps, researchers may be able to determine what types of polyps will turn into cancer and which may not.
Read full article
Stony Brook University Cancer Center Receives New Dose of Philanthropy
Cancer Prevention Fellowship Established with $1 Million Endowment from George and Olga Tsunis
As a symbol of their shared commitment to fighting cancer and as a nod to their great pride in their Greek ancestry, George and Olga Tsunis have established an endowed fellowship for an MD or PhD pursuing biomedical research at the Stony Brook University Cancer Center. The Tsunis Fellowship for Cancer Prevention has been created to attract a well-qualified scholar from Greece or of Greek decent, with the goal of training these physicians and scientists at Stony Brook, and then returning them to Greece to help the country overcome its current difficulties.
The George and Olga Tsunis Fellow will learn the process of how new and novel drugs can be developed for the treatment of cancer. Such knowledge could be applied in Greece to improve the treatment of cancer patients; conduct clinical trials of new drugs; and foster academia-pharmaceutical industry interactions on drug development.
Patricia Thompson-Carino, PhD, Named Deputy Director for Research
Yusuf A. Hannun, MD, Director of the Stony Brook University Cancer Center, Vice Dean for Cancer Medicine, and the Joel Kenny Professor of Medicine, has announced the appointment of Patricia Thompson, PhD, to the position of Deputy Director for Research at Stony Brook University Cancer Center. In her new role, Dr. Thompson will oversee all research activities in the Cancer Center, as well as develop overall strategic plans for the Cancer Center in conjunction with Dr. Hannun and Samuel Ryu, MD, Deputy Director, Clinical Affairs, Cancer Center.
Dr. Thompson joined Stony Brook in 2014 as Professor of Pathology and Associate Director for Basic Research in the Cancer Center. Her research is focused primarily on the discovery and validation of biomarkers to identify individuals at greatest risk for cancer recurrence.
Dr. Thompson leads a nationally prominent research program that concentrates on the evolution of molecular and cellular changes that occur during the development of colorectal and breast cancer. Because those cancers both have an inflammatory component and an immune element, the research explores what is shared by them that could be common targets for prevention and treatment.
“Our goal is to help advance the development of more precise and effective targeted therapies,” said Dr. Thompson. “The better we understand the way cancer progresses, the better we will be at discovering methodologies for treating patients with cancer.”
The author of more than 100 important research manuscripts, Dr. Thompson is a member of a number of national grant review panels, and has served as principal investigator for several research grants from the National Cancer Institute (NCI).
“Dr. Thompson has an outstanding track record of achievements, and since joining Stony Brook she has taken on significant leadership roles,” said Dr. Hannun. “She brings special and unique abilities in the war against cancer, and will help the Cancer Center continue to push the envelope in diagnosis, treatment and prevention.”